Pediatric Praziquantel Consortium
Pediatric Praziquantel Consortium at the NTD Summit
The 5th anniversary of the World Health Organization's roadmap on NTDs and the London Declaration are celebrated at the NTD summit in Geneva on April 19-22. The Pediatric Praziquantel Consortium will join the summit to showcase its continuous contribution in the overall schistosomiasis field.
Pediatric Praziquantel Consortium awarded US$4.7 million GHIT grant
On 30 Mar 2017, the GHIT Fund announced that it will continue to support the Pediatric Praziquantel Consortium. The grant of US$4.7m will allow the Consortium to perform its phase III program and submit the registration file.
A story of schistosomiasis infection in Ghana
A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.
The pediatric formulation
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that will use small, orally dispersible tablets with an acceptable taste.